Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism

Hypertension

Volumn 51, Issue 4 PART 2 SUPPL., 2008, Pages 1177-1183

  Karatas, Aysun ^a   Hegner, Björn ^a   De Windt, Leon J ^b   Luft, Friedrich C ^c   Schubert, Carola ^a   Gross, Volkmar ^c   Akashi, Yoshihiro J ^a   Gürgen, Dennis ^a   Kintscher, Ulrich ^a   Da Costa Goncalves, Andrey C ^c   Regitz Zagrosek, Vera ^a   Dragun, Duska ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Calcineurin; Fibrosis; Heart; Hypertrophy; Inflammation; Kidney; MCIP1; NFATc2

Indexed keywords

CALCINEURIN; CALCINEURIN ABETA; DEOXYCORTICOSTERONE ACETATE; HYDRALAZINE; MINERALOCORTICOID; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; MALE; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCINEURIN; DESOXYCORTICOSTERONE; ECHOCARDIOGRAPHY; FEMALE; HYDRALAZINE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MINERALOCORTICOIDS; NFATC TRANSCRIPTION FACTORS; PHOSPHORYLATION; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; SODIUM CHLORIDE, DIETARY;

EID: 40849092823     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.107938     Document Type: Article

References (35)

1. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov. 2006;5:225-239.
2. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995;25:515-533.
3. Agabiti-Rosei E, Muiesan ML. Left ventricular hypertrophy and heart failure in women. J Hypertens. 2002;20(suppl):S34-S38.
4. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000;11:319-329.
5. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688-708.
6. Deschepper CF, Llamas B. Hypertensive cardiac remodeling in males and females: From the bench to the bedside. Hypertension. 2007;49:401-407.
7. Pechere-Bertschi A, Burnier M. Gonadal steroids, salt-sensitivity and renal function. Curr Opin Nephrol Hypertens. 2007;16:16-21.
8. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 2003;64:1772-1779.
9. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens. 2005;14:235-241.
10. Ortiz PA, Garvin JL. Intrarenal transport and vasoactive substances in hypertension. Hypertension. 2001;38:621-624.
11. Ouchi Y, Share L, Crofton JT, Iitake K, Brooks DP. Sex difference in the development of deoxycorticosterone-salt hypertension in the rat. Hypertension. 1987;9:172-177.
12. Bueno OF, van Rooij E, Molkentin JD, Doevendans PA, De Windt LJ. Calcineurin and hypertrophic heart disease: novel insights and remaining questions. Cardiovasc Res. 2002;53:806-821.
13. Takeda Y, Yoneda T, Demura M, Usukura M, Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation. 2002;105:677-679.
14. Gross V, Tank J, Obst M, Plehm R, Blumer KJ, Diedrich A, Dietrich A, Jorgan J, Luft FC. Autonomic nervous system and blood pressure regulation in RGS-2-deficient mice. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1134-R1142.
15. Katholi RE, Naftilan AJ, Oparil S. Importance of renal sympathetic tone in the development of DOCA-salt hypertension in the rat. Hypertension. 1980;2:266-273.
16. Evans JM, Ziegler MG, Patwardhan AR, Ott JB, Kim CS, Leonelli FM, Knapp CF. Gender differences in autonomic cardiovascular regulation: spectral, hormonal, and hemodynamic indexes. J Appl Physiol. 2001;91:2611-2618.
17. Convertino VA. Gender differences in autonomic functions associated with blood pressure regulation. Am J Physiol. 1998;275:R1909-R1920.
18. Saleh MC, Connell BJ, Saleh TM. Autonomic and cardiovascular reflex responses to central estrogen injection in ovariectomized female rats. Brain Res. 2000;879:105-114.
19. Schroeder C, Adams F, Boschmann M, Tank J, Haertter S, Diedrich A, Biaggioni I, Luft FC, Jordan J. Phenotypical evidence for a gender difference in cardiac norepinephrine transporter function. Am J Physiol Regul Integr Comp Physiol. 2004;286:R851-R856.
20. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail. 2002;8:101-107.
21. Titze J, Luft FC, Bauer K, Dietsch P, Lang R, Veelken R, Wagner H, Eckardt KU, Hilgers KF. Extrarenal Na+ balance, volume, and blood pressure homeostasis in intact and ovariectomized deoxycorticosterone-acetate salt rats. Hypertension. 2006;47:1101-1107.
22. Wang Q, Hummler E, Nussberger J, Clément S, Gabbiani G, Brunner HR, Burnier M. Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. J Am Soc Nephrol. 2002;13:1509-1516.
23. Wang Q, Domenighetti AA, Pedrazzini T, Burnier M. Potassium supplementation reduces cardiac and renal hypertrophy independent of blood pressure in DOCA/salt mice. Hypertension. 2005;46:547-554.
24. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94:110-118.
25. van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res. 2004;63:487-499.
26. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
27. van Rooij E, Doevendans PA, Crijns HJ, Heeneman S, Lips DJ, van Bilsen M, Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De Windt LJ. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res. 2004;94:e18-e26.
28. Pedram A, Razandi M, Aitkenhead M, Levin ER. Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem. 2005;280:26339- 26348.
29. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC. Inhibition of calcineurin-NFAT hypertrophy signalling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99:11363-11368.
30. Satonaka H, Suzuki E, Nishimatsu H, Oba S, Takeda R, Goto A, Omata M, Fujita T, Nagai R, Hirata Y. Calcineurin promotes the expression of monocyte chemoattractant protein-1 in vascular myocytes and mediates vascular inflammation. Circ Res. 2004;94:693-700.
31. Behr TM, Wang X, Aiyar N, Coatney RW, Li X, Koster P, Angermann CE, Ohlstein E, Feuerstein GZ, Winaver J. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation. 2000;102:1315-1322.
32. Young MJ, Lam EY, Rickard AJ. Mineralocorticoid receptor activation and cardiac fibrosis. Clin Sci (Lond). 2007;112:467-475.
33. Tumlin JA, Lea JP, Swanson CE, Smith CL, Edge SS, Someren JS. Aldosterone and dexamethasone stimulate calcineurin activity through a transcription- independent mechanism involving steroid receptor-associated heat shock proteins. J Clin Invest. 1997;99:1217-1223.
34. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999;56:1627-1637.
35. Wang J, Want N, Xie J, Walton SC, McKown RL, Raab RW, Ma P, Beck SL, Coffman GL, Hussaini IM, Laurie GW. Restricted epithelial proliferation by lacritin via PKCa-dependent NFAT and mTOR patways. J Cell Biol. 2006;174:689-700.